What is Supartz (5×2.5mg)?
Supartz (5×2.5mg)is made from pure animal free hyaluronic acid and is used to treat knee joint pain by injecting into area to offer six months pain relief. The process is referred to as viscosupplementation, where the joints are injected (supplemented) with healthy hyaluronic acid lubricant which means that patients can be mobile and independent to carry out their normal daily activities again. This process is much more effective then taking drugs orally to contain the pain.
An effective gel treatment to give patients cushioning between knee joints to minimise joint pain caused by osteoarthritis.
What is so unique about Supartz?
Supartz extinguishes pain from osteoarthritis for half a year.
Patients are given one injection every 3-5 weeks.
Many have reported immediate pain relief after the initial treatment.
Supartz imitates the fluid found in knee joints.
Made from hyaluronic acid, a natural substance found inside the human body. Its key properties are to keep the skin hydrated whilst adding plumpness. HA naturally breaks down in the body during metabolism and is then replaced. However as we gets older and our metabolism slows down, replacement of HA is less often which results in less hydrated skin and less volume in the skin.
Who should not use Supartz?
Individuals with skin infections or any skin related diseases, especially at the proposed site of injection.
What are the associated side effects with Supartz?
Joint swelling and injection site pain have been the most common side effects.
Trust Filler Medicals were involved in the launch of Botox®, Dermal Filler and other cosmetics to the market. Over the years we have been at the centre of the industry throughout its development and growth. We have personally visited hundreds of practitioners and clinics, attended industry conferences and meetings at home and abroad, and have developed working relationships with national and international practitioners, doctors, experts, suppliers and distributors.
As the industry has evolved, it has become increasingly complex and difficult to access clear information regarding treatments, products, legislation, statistics and clinical information.